Biogen Idec Says Long-Lasting Hemophilia Drug Meets Safety Goals

Before you go, we thought you'd like these...
Before you go close icon
Biogen Idec (BIIB) and Swedish Orphan Biovitrum said a potential hemophilia B treatment has metsafety goals in an early-stage study.

The study involved 14 previously treated patients, and the data showed that the drug, rFIXFc, was well tolerated and demonstrated an approximately three-fold increase in half-life, compared to previous data for existing therapies. That would give provide prolonged protection with a single dose.

The study was presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010. Based on this study, the companies said they'll conduct a global registrational trial of the safety and effectiveness of the drug with 75 patients.

Hemophilia is a rare, inherited disorder in which patients have an impaired ability for blood clotting, leading to excessive bleeding. Current treatments require intravenous injections twice a week. This drug, the companies hope, would reduce the injections to once a week.

Read Full Story

Markets

S&P 500 2,275.19 11.50 0.51%
DJIA 19,829.94 97.54 0.49%
NASDAQ 5,568.08 28.00 0.51%
DAX 11,626.55 29.66 0.26%
HANG SENG 22,885.91 -164.05 -0.71%
NIKKEI 225 19,137.91 65.66 0.34%
USD (per EUR) 1.07 0.00 0.16%
USD (per CHF) 1.01 0.00 -0.09%
JPY (per USD) 114.88 -0.09 -0.08%
GBP (per USD) 1.23 0.00 -0.11%

From Our Partners